SG10201501561XA - Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination - Google Patents
Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccinationInfo
- Publication number
- SG10201501561XA SG10201501561XA SG10201501561XA SG10201501561XA SG10201501561XA SG 10201501561X A SG10201501561X A SG 10201501561XA SG 10201501561X A SG10201501561X A SG 10201501561XA SG 10201501561X A SG10201501561X A SG 10201501561XA SG 10201501561X A SG10201501561X A SG 10201501561XA
- Authority
- SG
- Singapore
- Prior art keywords
- vaccination
- prevention
- treatment
- antibody therapy
- cancers associated
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000009175 antibody therapy Methods 0.000 title 1
- 230000003834 intracellular effect Effects 0.000 title 1
- 102000027450 oncoproteins Human genes 0.000 title 1
- 108091008819 oncoproteins Proteins 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26489209P | 2009-11-30 | 2009-11-30 | |
| US34521910P | 2010-05-17 | 2010-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201501561XA true SG10201501561XA (en) | 2015-04-29 |
Family
ID=44066805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201501561XA SG10201501561XA (en) | 2009-11-30 | 2010-11-30 | Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
| SG2012039368A SG181113A1 (en) | 2009-11-30 | 2010-11-30 | Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012039368A SG181113A1 (en) | 2009-11-30 | 2010-11-30 | Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2506864B1 (en) |
| CN (1) | CN102753191B (en) |
| SG (2) | SG10201501561XA (en) |
| WO (1) | WO2011065923A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201903119QA (en) * | 2011-09-06 | 2019-05-30 | Agency Science Tech & Res | Polypeptide vaccine |
| WO2013063613A2 (en) * | 2011-10-28 | 2013-05-02 | University Of Maryland | Methods and compositions related to intracellular neutralization by igg |
| SG11201811068YA (en) * | 2016-06-14 | 2019-01-30 | Agency Science Tech & Res | Prl3 antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5156841A (en) * | 1988-08-26 | 1992-10-20 | United States Of America | Anti-tumor vaccine |
| DK3360571T3 (en) * | 2007-05-03 | 2021-01-04 | Agency For Science Tech And Research Astarstar | Antibodies that bind to an intracellular PRL-1 or PRL-3 polypeptide |
| EP2185176B1 (en) * | 2007-08-10 | 2016-07-06 | Agency for Science, Technology And Research | Vhz for diagnosis and treatment of cancer |
-
2010
- 2010-11-30 SG SG10201501561XA patent/SG10201501561XA/en unknown
- 2010-11-30 WO PCT/SG2010/000449 patent/WO2011065923A1/en active Application Filing
- 2010-11-30 EP EP10833678.5A patent/EP2506864B1/en active Active
- 2010-11-30 CN CN201080063334.3A patent/CN102753191B/en active Active
- 2010-11-30 SG SG2012039368A patent/SG181113A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2506864A4 (en) | 2013-08-21 |
| EP2506864B1 (en) | 2016-07-27 |
| WO2011065923A1 (en) | 2011-06-03 |
| SG181113A1 (en) | 2012-07-30 |
| CN102753191B (en) | 2016-08-24 |
| CN102753191A (en) | 2012-10-24 |
| EP2506864A1 (en) | 2012-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245119A1 (en) | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents | |
| HK1245128A1 (en) | Antigens and vaccines directed against human enteroviruses | |
| HK1200740A1 (en) | Combination therapy of antibodies against human csf-1r and uses thereof csf-1r | |
| HUE051674T2 (en) | Means and methods for the prediction of treatment response of a cancer patient | |
| IL215402A0 (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
| ZA201107128B (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
| EP2844736A4 (en) | Modified bacteria and uses thereof for treatment of cancer or tumor | |
| ZA201106730B (en) | Methods of treatment using combination therapy | |
| EP2591363A4 (en) | Diagnosis and treatment of breast cancer | |
| EP2652508A4 (en) | The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer | |
| HRP20170225T1 (en) | Phosphaplatins and their use for treatment of cancers | |
| EP2652506A4 (en) | The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer | |
| ZA201307641B (en) | Human tissue factor antibody and uses thereof | |
| EP2700652A4 (en) | Diagnosis and treatment of cancer using anti-itm2a antibody | |
| HK1201154A1 (en) | Combination therapy using anti-cd20 antibody and human il-15 cd20 il-15 | |
| ZA201300762B (en) | Novel combination therapy for the treatment of cancer | |
| IL228579A0 (en) | Methods for predicting and improving the survival of gastric cancer patients | |
| EP2420515A4 (en) | Diagnosis and treatment of cancer using anti-tmprss11e antibody | |
| SG10201608967WA (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
| SG10201501561XA (en) | Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination | |
| PL388252A1 (en) | Combination therapy of colorectal cancer | |
| GB201412831D0 (en) | Detection and treatment of breast cancer | |
| GB201017356D0 (en) | Combination treatment of cancer |